

Bristol Myers Squibb (USA): Merger with Celgene Corporation Changes in Russell RAFI™ Index Series

18 November 2019

Subject to the completion of the cash and stock merger between Bristol Myers Squibb (USA, constituent) and Celgene Corporation (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell RAFI Global Index	21 November 2019
Russell RAFI Global Large Company Index	21 November 2019
Russell RAFI Developed Index	21 November 2019
Russell RAFI Developed Large Company Index	21 November 2019
Russell RAFI US Index	21 November 2019
Russell RAFI US Large Company Index	21 November 2019

^{*}Based upon the stock merger terms of one share of Bristol Myers Squibb for every share of Celgene Corporation held.

For further information please contact FTSE Russell Client Services at $info@ftserussell.com\ or\ call$:

Australia +1800 653 680 Hong Kong +852 2164 3333 Japan +81 3 4563 6346 London +44 (0) 20 7866 1810 New York +1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2019 FTSE Russell